DK1713473T3 - Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD - Google Patents

Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD

Info

Publication number
DK1713473T3
DK1713473T3 DK05706979.1T DK05706979T DK1713473T3 DK 1713473 T3 DK1713473 T3 DK 1713473T3 DK 05706979 T DK05706979 T DK 05706979T DK 1713473 T3 DK1713473 T3 DK 1713473T3
Authority
DK
Denmark
Prior art keywords
anticholinergics
glucocorticoids
copd
asthma
combination
Prior art date
Application number
DK05706979.1T
Other languages
Danish (da)
English (en)
Inventor
Joachim Goede
Joachim Maus
Peter Juergen Cnota
Istvan Szelenyi
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Application granted granted Critical
Publication of DK1713473T3 publication Critical patent/DK1713473T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05706979.1T 2004-02-06 2005-01-24 Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD DK1713473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
PCT/EP2005/000652 WO2005074918A1 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd

Publications (1)

Publication Number Publication Date
DK1713473T3 true DK1713473T3 (da) 2013-06-17

Family

ID=34837533

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05706979.1T DK1713473T3 (da) 2004-02-06 2005-01-24 Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD

Country Status (16)

Country Link
US (2) US20050175548A1 (enExample)
EP (1) EP1713473B1 (enExample)
JP (1) JP4819699B2 (enExample)
CN (1) CN100569235C (enExample)
AU (1) AU2005210085B2 (enExample)
CA (1) CA2551780C (enExample)
DK (1) DK1713473T3 (enExample)
ES (1) ES2413011T3 (enExample)
HR (1) HRP20130460T1 (enExample)
NO (1) NO336882B1 (enExample)
NZ (1) NZ548300A (enExample)
PL (1) PL1713473T3 (enExample)
PT (1) PT1713473E (enExample)
RU (1) RU2440813C2 (enExample)
SI (1) SI1713473T1 (enExample)
WO (1) WO2005074918A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2389231T3 (es) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
RS53391B2 (sr) 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
CA2785349C (en) 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
IN2015DN01018A (enExample) * 2012-08-09 2015-06-26 Chase Pharmaceuticals Corp
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
BR112015022784B1 (pt) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc Método de condicionamento de material cristalino micronizado e sistemas de condicionamento
DK3089735T3 (en) 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
CN113350352B (zh) 2015-03-23 2024-09-10 天莅生物科技私人有限公司 呼吸性疾病的治疗
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения
WO2020093097A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Compounds and compositions for the treatment of respiratory diseases
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers
CN120360953B (zh) * 2025-06-24 2025-09-05 成都第一制药有限公司 一种用于copd治疗的莨菪烷类生物碱组合物及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0706513T1 (en) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
RU2221552C2 (ru) 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US6203779B1 (en) * 1999-03-19 2001-03-20 Charlie Ricci Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
JP2004530705A (ja) 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのpde4インヒビター及びチオトロピウム又はその誘導体の組み合わせ
WO2002096463A1 (en) 2001-05-25 2002-12-05 Pfizer Inc. A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AU2003230689B2 (en) * 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
DE10216429A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
US20040053902A1 (en) 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
WO2004084897A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
MXPA05010160A (es) 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
CN100520419C (zh) * 2003-07-11 2009-07-29 Nxp股份有限公司 改进的频率确定
NZ548302A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
JP2007524698A (ja) 2004-02-27 2007-08-30 アルタナ ファルマ アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
ES2389231T3 (es) 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias

Also Published As

Publication number Publication date
EP1713473B1 (en) 2013-03-13
ES2413011T3 (es) 2013-07-15
PT1713473E (pt) 2013-05-13
AU2005210085B2 (en) 2010-06-24
NZ548300A (en) 2010-04-30
CA2551780C (en) 2013-02-26
PL1713473T3 (pl) 2013-08-30
RU2006132038A (ru) 2008-03-20
CA2551780A1 (en) 2005-08-18
US10537550B2 (en) 2020-01-21
RU2440813C2 (ru) 2012-01-27
NO20063879L (no) 2006-11-01
CN1913883A (zh) 2007-02-14
JP2007520508A (ja) 2007-07-26
NO336882B1 (no) 2015-11-23
HRP20130460T1 (hr) 2013-06-30
HK1098356A1 (zh) 2007-07-20
WO2005074918A1 (en) 2005-08-18
CN100569235C (zh) 2009-12-16
SI1713473T1 (sl) 2013-06-28
US20050175548A1 (en) 2005-08-11
US20080300226A1 (en) 2008-12-04
JP4819699B2 (ja) 2011-11-24
AU2005210085A1 (en) 2005-08-18
EP1713473A1 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
DK1713473T3 (da) Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1761222T3 (da) Indretninger og fremgangsmåder til magnetisk manipulering af intravaskulære indretninger
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
DK1856374T3 (da) Sammensætning og fremgangsmåde til fremstilling af et støttemiddel
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
DK1725253T3 (da) Medikamenter og fremgangsmåder til behandling af hovedpine
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2029746T3 (da) Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
DK1911358T3 (da) Ny sammensætning til forbedring af hudkvalitet og fremgangmåde til fremstilling deraf
DK1919450T3 (da) Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
DK1948695T3 (da) Immunogene sammensætninger og fremgangsmåder til andvendelse
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK2043671T3 (da) Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber